Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Chemotherapy. University Hospital (Vienna), Vienna, Austria

Survival: 29.5 months
Toxicity Grade: 4
Treatments: Chemotherapy
Drugs: Gemzar
Country: Austria
City/State/Province: Vienna
Hospital: University Hospital (Vienna)
Journal: Link
Date: 3/2005

Patients: This Phase III study involved 259 women with metastatic breast cancer. The patients were randomly placed into two groups: Group A had 124 patients (median age 53). Metastatic sites included liver, lung, bone, and lymph node. None of the patients had received anthracyclines prior to treatment.

Treatment: For Group A, the treatment involved three chemotherapeutic agents: gemcitabine, epirubicin, paclitaxel.

Toxicity: In Group A, grade 3-4 toxicities included: neutropenia, thrombocytopenia, anemia, nausea/vomiting, mucositis, allergy, neurosensory toxicity, hepatic toxicity, diarrhea, cardiovascular toxicity, and skin rashes.

Results: The median overall survival was 29.5 months for Group A.

Support: Eli Lilly and Company, Bristol-Myers Squibb, and Pharmacia Upjohn provided financial support for this trial. Eli Lilly manufactures and markets gemcitabine. Bristol-Myers Squibb manufactures and markets cyclophosphamide and paclitaxel. Pharmacia Upjohn manufactures and markets epirubicin. Pharmacia Upjohn distributes fluorouracil.

Correspondence: Christoph C. Zielinski, MD

E-mail to a Friend Email Physician More Information